you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes

October 2012

New generics plus bladder cancer concerns mean you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes.

Actos is one of the top 25 prescribed drugs in the U.S...and lower prices for the generic could tempt more prescribers to use it.

But some providers are reluctant to use it due to growing concerns about bladder cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote